ID   LIM2551
AC   CVCL_4443
SY   LIM 2551; LIM-2551
DR   BioSample; SAMN07624418
DR   cancercelllines; CVCL_4443
DR   CBA; CBA-0170
DR   ColonAtlas; LIM2551
DR   Cosmic; 1238059
DR   Cosmic; 1486141
DR   Cosmic; 1803947
DR   Cosmic; 2301995
DR   ECACC; 12070505
DR   GEO; GSM1346881
DR   GEO; GSM1448076
DR   GEO; GSM3145718
DR   Wikidata; Q54902541
RX   PubMed=19378335;
RX   PubMed=24755471;
RX   PubMed=25926053;
CC   From: Ludwig Institute for Cancer Research, Melbourne Branch; Melbourne; Australia.
CC   Microsatellite instability: Instable (MSI) (PubMed=19378335; PubMed=24755471; PubMed=25926053).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=19378335; PubMed=24755471).
CC   Sequence variation: Mutation; HGNC; HGNC:16712; FBXW7; Simple; p.Thr578Pro (c.1732A>C); Zygosity=Unspecified (PubMed=24755471).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=24755471).
CC   Sequence variation: Mutation; HGNC; HGNC:6769; SMAD3; Simple; p.Ala202Thr (c.604G>A); ClinVar=VCV001171415; Zygosity=Unspecified (PubMed=24755471).
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Miscellaneous: Sex of donor from original lab book of Whitehead, Robert H. and from patient surgeon through a personal communication of Capes-Davis, Amanda.
CC   Derived from site: In situ; Colon, transverse; UBERON=UBERON_0001157.
ST   Source(s): CBA=CBA-0170; PubMed=25926053
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 8,10
ST   D16S539: 11
ST   D18S51: 15,16
ST   D19S433: 12
ST   D21S11: 28,33.2
ST   D2S1338: 17,23
ST   D3S1358: 16,17
ST   D5S818: 12,16
ST   D7S820: 9,11
ST   D8S1179: 12,13
ST   FGA: 22,23,24
ST   TH01: 6,9.3
ST   TPOX: 8,11
ST   vWA: 17,19
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 31
//
RX   PubMed=19378335; DOI=10.1002/ijc.24289;
RA   Zhang H.-H., Walker F.E., Kiflemariam S., Whitehead R.H., Williams D.,
RA   Phillips W.A., Mikeska T., Dobrovic A., Burgess A.W.;
RT   "Selective inhibition of proliferation in colorectal carcinoma cell
RT   lines expressing mutant APC or activated B-Raf.";
RL   Int. J. Cancer 125:297-307(2009).
//
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//